Short answer
Travere Therapeutics, Inc. (TVTX) filed its Q3 2025 10-Q quarterly report on Oct 30, 2025 for the quarter ended Sep 30, 2025. Quarterly revenue was $165M (up 162.1% year over year) with net income of $26M.
Q3 2025 key financials · XBRL
- Revenue
- $165M
- +162.1% YoY · +44.0% QoQ
- Net income
- $26M
- +146.9% YoY · +301.5% QoQ
- Operating margin
- 15.1%
- EPS (diluted)
- $0.29
- +141.4% YoY · +307.1% QoQ
Source: XBRL data from the Travere Therapeutics, Inc. (TVTX) Q3 2025 10-Q on SEC EDGAR. USD.
Travere Therapeutics, Inc. Q3 2025 10-Q analysis
AI summary of MD&A and risk factor updates
Risk Factors
- New commercialization risk: FDA full approval of FILSPARI in Sept 2024 replacing prior accelerated approval in Feb 2023 requires expanded U.S. sales force training and market adoption efforts
- Most material update: Expanded risks on third-party commercialization outside U.S. due to CSL Vifor acquisition by CSL Limited and possible reduced marketing support
- Regulatory risk: $6.2M invoice paid in Oct 2024 relating to French authority price recalculation on Kolbam sales 2015-2020, appeal ongoing with uncertain final liability
- Operational risk: Dependence on third-party sole-source manufacturers and distributors risks supply disruptions and increased cost from tariff or trade policy changes
- Financial risk: Exposure to pricing pressure from U.S. MFN drug pricing executive order (May 2025) and ongoing healthcare payer reimbursement restrictions affecting product demand and pricing
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Travere Therapeutics, Inc. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.